Asia Invests in Laboratory Tools for Medicinal Chemistry
News May 01, 2006
Radleys has announced sales of its parallel chemistry and laboratory reactor products have contributed to a 400% growth in its Asian business during 2004-5 and 2005-6.
Reflecting on the spectacular business growth, Mark Radley (Managing Director) commented, "In recent years a growing proportion of our traditional pharmaceutical and biotech industry customers in Europe and North America have started to relocate part of their R&D to Asia."
"Consequently we have increased our resource allocation to the region and have seen companies including SABIC, Nicholas Piramal, Altana, GVK, Syngene, Dr Reddys, Advinus and Torrent investing in technology such as the Carousel, GreenHouse and Lara product ranges, to enable them to either win contracts from US or European pharma/biotech companies or to develop their own R&D programs."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018